Tag: GlobeNewswire

Milestone advances Phase 3 program toward topline results expected in mid 2027

HIGH POINT, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that the Company has completed enrollment of its Phase 3 Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (CATT1) study. A total of 166 patients have been randomized in the study evaluating cadisegliatin, a potential first-in-class oral, liver-selective glucokinase activator that has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to insulin for the treatment of T1D.

“Completing enrollment for the CATT1 study is a significant milestone for vTv, and we’re deeply grateful to the study participants whose commitment made this possible,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. “Cadisegliatin has the potential to reduce the risk of hypoglycemia, which remains a significant unmet need for people living with T1D, and we look forward to completing the study and reporting topline results in mid 2027.”

An estimated 9.5 million people worldwide live with T1D, and this number is projected to reach 14.7 million by 2040.ⁱ Despite advances in diabetes technology, significant gaps persist in achieving optimal day-to-day glycemic control,ⁱⁱ and hypoglycemia remains a daily burden on the lives of people living with T1D. The CATT1 study is evaluating the potential of cadisegliatin to reduce clinically significant hypoglycemia while improving overall glycemic control.

“This milestone is an important step forward for the cadisegliatin program,” said Thomas Strack, MD, Chief Medical Officer of vTv Therapeutics. “Our focus now is maintaining the quality and integrity of the study through completion and continuing the important work of advancing cadisegliatin development toward potential approval.”

About the Phase 3 CATT1 Study
Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (CATT1) (NCT06334133) is a randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of cadisegliatin over six months in individuals with T1D 18 years or older who are on multiple daily insulin injections or continuous subcutaneous insulin infusion, along with continuous glucose monitoring. Participants were randomized to receive cadisegliatin 800 mg once daily, cadisegliatin 800 mg twice daily, or placebo. The primary efficacy endpoint will assess the incidence of level 2 and level 3 hypoglycemic events. Secondary endpoints include changes in hemoglobin A1c (HbA1c), time in target glucose range, and the incidence of diabetic ketoacidosis in cadisegliatin-treated participants compared with placebo. Additional information about the study is available at https://clinicaltrials.gov/study/NCT06334133.

About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small-molecule, glucokinase activator being investigated in the U.S. as a potential first-in-class adjunctive treatment for T1D. In nonclinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently of insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and its safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, a potential first-in-class oral glucokinase activator being investigated in a U.S. Phase 3 study for the treatment of T1D. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn.

Forward-Looking Statements
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other variations or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, the anticipated effect of Phase 3 topline data on the Company, the benefits of cadisegliatin to people living with T1D, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

ⁱ Ogle G, Wang F, Haynes A, et al, Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0. Diabetes Research and Clinical Practice. 2025; 225. doi: 10.1016/j.diabres.2025.112277.
ⁱⁱ Jacobs PG, Levy CJ, Brown SA, et al. Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems. J Diabetes Sci Technol. 2025;19(4):937-949. doi: 10.1177/19322968251338754.

~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the RaniPill^® Capsule™ platform technology has been accepted into the U.S. Food and Drug Administration (FDA) Emerging Technology Program (ETP).

The FDA’s Emerging Technology Program, administered within the Agency’s Center for Drug Evaluation and Research (CDER), is designed to support the development and implementation of innovative approaches to pharmaceutical product design and manufacturing. Technologies accepted into the program must demonstrate the potential to improve pharmaceutical product quality and incorporate novel elements for which the FDA has limited review or inspection experience. Participation provides Rani with early, direct engagement with the FDA’s Emerging Technology Team to address technical and regulatory considerations related to the RaniPill platform, including through pre-submission meetings and potential site visits. Importantly, these interactions can address the broader applicability of the underlying technology rather than being limited to individual drug products.

“Our acceptance into the FDA’s Emerging Technology Program reflects the Agency’s recognition of the RaniPill^® platform as a novel and innovative approach to the oral delivery of biologics,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “This program enables direct, collaborative access to the FDA on a technology as novel as Rani’s, and we expect that engagement to be especially valuable as we work to automate our vertically integrated manufacturing process in anticipation of broader clinical use. Combined with our rare disease, immunology, and obesity focused partnerships with Chugai, ProGen and PegBio, this milestone reflects our continued confidence in the RaniPill platform’s potential as an alternative to injectable biologics. We look forward to working closely with the FDA as we continue to advance the platform.”

About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill^® Capsule™, a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill^® Capsule technology.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the potential of Rani’s RaniPill^® platform to convert injectable biologics into oral therapies, and to address unmet needs in the treatment of patients requiring injectable biologics, the anticipated value of Rani’s engagement with the FDA under the Emerging Technology Program, Rani’s plans to automate its vertically integrated manufacturing process in anticipation of broader clinical use, Rani’s expectations regarding its partnerships with Chugai, ProGen and PegBio and the continued development of the RaniPill platform. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “continue,” “intend,” “look forward to,” “potential,” “expect,” “will,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rani’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rani’s business in general and the other risks described in Rani’s filings with the Securities and Exchange Commission, including Rani’s annual report on Form 10-K for the year ended December 31, 2025, and subsequent filings and reports by Rani. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Rani undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact:
investors@ranitherapeutics.com

Media Contact:
media@ranitherapeutics.com

Continued purchases and organic accumulation drive approximately 11% growth in SOL holdings since the Company’s August 12 Earnings Update

Preliminary September 30 estimates indicate double-digit SPS growth and NAV per share growth of more than 100%, both measured from August 12

In Q3, SOL outperformed the Nasdaq-100 by 56%, and DFDV outperformed SOL by 1.5x over that same period

CHAD brings Digital Credit 2.0 to income investors: a 13% annual dividend rate supported by a productive SOL treasury

BOCA RATON, FL, Oct. 05, 2026 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced that it has added approximately 26,203 SOL to its treasury since September 28, 2026, bringing total holdings to approximately 2,564,212 SOL and SOL equivalents worth $302M.

The latest increase brings total SOL and SOL equivalents growth to approximately 11% since the Company’s Q2 earnings report on August 12. With the recently established $300 million CHAD ATM providing an additional source of growth capital, the Company believes its SOL accumulation flywheel is continuing to gain momentum.

Preliminary Q3 Estimates: Per-Share Growth Metrics and Stronger Liquidity
Alongside continued accumulation, the Company expects to report substantial growth in its per-share metrics and a stronger balance sheet as of September 30, 2026. Based on preliminary estimates, the Company expects to report the following changes as of September 30, 2026, compared with August 12, 2026:

• Double-digit growth in SOL per share (“SPS”).
• More than 100% growth in net asset value (“NAV”) per share.
• Double-digit growth in total SOL and SOL equivalents.
• A reduction in notional SOL-denominated borrowings.
• More than 100% growth in cash and cash equivalents.

These preliminary estimates reflect roughly seven weeks of rapid progress in expanding the Company’s SOL treasury, increasing SOL exposure per common share, and strengthening liquidity.

“The DFDV ship is flying at lightning speed. We have continued buying SOL and have grown our treasury by 11% since August 12,” said Joseph Onorati, Chief Executive Officer of DeFi Development Corp. “Those gains are adding up. We expect to report double digit growth in SOL per share and more than a doubling of NAV per share since our August update. Our focus remains on making each common share represent more SOL over time.”

The Company intends to continue accumulating SOL through disciplined capital deployment and organic treasury growth, while putting its holdings to work through staking and validator operations. Its capital allocation strategy remains focused on accretive growth for common shareholders alongside prudent management of liabilities and liquidity.

The anticipated September 30 metrics are preliminary, remain subject to finalization, and may differ from the Company’s final reported results. See the forward-looking statements and supplemental metric disclosures at the end of this press release.

CHAD: First Dividend Marks a Milestone in Digital Credit 2.0
On October 1, 2026, DFDV paid CHAD’s first dividend, marking a milestone for its Nasdaq-listed variable-rate preferred stock. CHAD currently carries a 13% annual dividend rate on its $10 stated amount, equivalent to $1.30 per share annually at the current rate, with dividend payments continuing each business day when declared.

With payments underway, the Company is focused on expanding investor awareness, market access, and liquidity as it works toward establishing CHAD at its $10 stated amount and scaling it as a source of capital for DFDV’s next phase of growth.

The Company views CHAD as Digital Credit 2.0: preferred equity supported by a productive treasury. Through staking and validator operations, DFDV’s SOL holdings generate recurring rewards and fees, providing an organic source of income to support dividend obligations. The Company continues to maintain ample dividend coverage, while additional SOL accumulation can expand the treasury’s earning capacity over time.

“CHAD is fuel for the DFDV engine and central to our next phase of growth,” said Joseph Onorati, Chief Executive Officer of DeFi Development Corp. “It opens our strategy to income investors and gives us another source of capital to accumulate SOL and expand the treasury’s earning power. Our focus now is on building investor awareness, deepening liquidity, and establishing CHAD at its $10 stated amount.”

“We see a significant opportunity to scale CHAD from here,” continued Onorati. “Trading at par would position us to raise additional perpetual capital on terms that support accretive growth for common shareholders, while offering CHAD holders a compelling income stream. That is the next phase we are working toward.”

Learn more about CHAD at www.defidevcorp.com/chad.

For more information, visit defidevcorp.com. To stay up to date with the latest developments and insights, subscribe to our blog.

About DeFi Development Corp.
DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to SOL. Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance (DeFi) opportunities and continues to explore innovative ways to support and benefit from Solana’s expanding application layer.

The Company is also an AI-powered online platform that connects the commercial real estate industry by providing value-add services and software subscriptions to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage. The Company’s data and software offerings are generally offered on a subscription basis as software as a service.

Forward Looking Statements and Metrics
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding expected September 30, 2026 metrics and growth in SPS, NAV per share, SOL holdings and cash balances; anticipated changes in borrowings and liquidity; future SOL accumulation and per-share accretion; capital raising and deployment, the anticipated issuance price of shares under the CHAD ATM program, the CHAD dividend rate, the declaration and payment of CHAD dividends, the intended use of proceeds, and the Company’s ability to expand its SOL treasury and increase revenue, and can be identified by words such as “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) fluctuations in the market price of SOL and any associated losses that the Company may incur as a result of a decrease in the market price of SOL; (ii) a failure for the demand for SOL, or activity on the SOL network, to continue to develop and grow we anticipate or at all; (iii) volatility in our stock price, including due to future issuances of common stock and securities convertible into common stock; (iv) the effect of and uncertainties related to the ongoing volatility in interest rates; (v) our ability to achieve and maintain profitability in the future; (vi) the impact on our business of the regulatory environment and complexities of complying with such environment, including changes in securities laws or other laws or regulations; (vii) changes in the accounting treatment relating to the Company’s SOL holdings; (viii) our ability to respond to general economic conditions; (ix) our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; (x) our ability to access sources of capital, including debt financing and other sources of capital to finance operations and growth; and (xi) the risk that the Company’s preliminary estimates as of September 30, 2026 differ materially from its final results; (xii) risks relating to CHAD, including that the dividend rate may be adjusted, that dividends are payable only when declared, that CHAD may trade below its stated amount and that staking and validator rewards may be insufficient to support dividend payments; (xiii) other risks and uncertainties more fully described in the section captioned “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and other reports we file with the SEC.

As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

SPS and NAV per share are supplemental analytical measures used by management to assess the Company’s treasury strategy and economic exposure attributable to common shareholders. For purposes of this release, NAV reflects the value of SOL and SOL equivalents, plus cash and cash equivalents, less SOL-denominated liabilities, outstanding principal of out-of-the-money convertible debt, other debt, and the aggregate notional amount of preferred equity. NAV per share reflects that amount divided by adjusted common shares outstanding, which includes ordinary shares outstanding, shares underlying restricted stock units and vested options, and applicable dilution from assumed exercise of in-the-money warrants and conversion of in-the-money convertible securities. Related adjustments to NAV reflect assumed warrant exercise proceeds and the removal of debt assumed converted, as applicable, to avoid double counting. SPS expresses the corresponding net SOL exposure per adjusted common share, with the SPS growth comparison applying the updated, liability-adjusted methodology and a SOL reference price to both measurement dates. These measures depend on valuation and capital structure assumptions and do not represent GAAP book value per share, liquidation proceeds, or shareholder investment returns. Preliminary estimates are not audited and remain subject to completion of the Company’s financial close and verification of underlying balances and share counts, and final results may differ materially.

Investor Contact:
ir@defidevcorp.com

Media Contact:
press@defidevcorp.com

BRENTWOOD, Tenn., Oct. 05, 2026 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today that it will release its 2026 third quarter financial results after the market closes on Wednesday, November 4, 2026. A live broadcast of CoreCivic’s conference call will begin at 10:00 a.m. central time (11:00 a.m. eastern time) on Thursday, November 5, 2026.

To participate via telephone and join the call live, please register in advance. Upon registration at https://edge.media-server.com/mmc/p/si7rqqax/lan/en/, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode.

Participants may access the audio-only webcast of the conference call from the Company’s website at www.corecivic.com under the “Events & Presentations” section of the “Investors” page. A replay of the webcast will be available for seven days.

About CoreCivic

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that help build safer, healthier, and more productive communities one person at a time through residential corrections, detention, and reentry management, complementary service offerings to the corrections industry that include pharmaceutical, transportation, and alternatives to incarceration, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. We have been a flexible and dependable partner for government for more than 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Contact:

Investors: Jeb Bachmann – Managing Director, Investor Relations – (615) 263-3024 Media: Steve Owen – Vice President, Communications – (615) 263-3107

– Expands patient access to opioid-sparing pain control and advances 5×30 strategy – 

BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic partnership with Molteni Farmaceutici to expand access to opioid-sparing postsurgical pain management across European markets. Through this partnership, Molteni Farmaceutici will receive exclusive rights to distribute and commercialize EXPAREL® (bupivacaine liposome injectable suspension), Pacira’s long-acting, local analgesic for postsurgical pain management, within the licensed territories.

“We are excited to announce another strategic partnership that advances our 5×30 growth strategy and reinforces our commitment to expanding patient access to best-practice opioid-sparing postsurgical pain management,” said Frank D. Lee, chief executive officer of Pacira BioSciences. “With Molteni Farmaceutici’s longstanding leadership in pain management and extensive distribution network across Europe, they are ideally positioned to unlock EXPAREL’s full potential in key European markets.”

“This agreement is highly complementary with Molteni’s strategic priorities, and represents an important step in Molteni’s international growth and expansion strategy, while adding an innovative and differentiated medicine to our portfolio. We believe EXPAREL represents a compelling opportunity to address the significant unmet need for effective postsurgical pain management across Europe,” said Gianluca Corbinelli, chief executive officer at Molteni Farmaceutici. “We look forward to bringing this important treatment to more patients and healthcare providers across the region.”

Under the terms of the agreement, Pacira will receive an undisclosed upfront payment, a supply price, and royalties on future commercial sales by Molteni Farmaceutici in licensed territories. Pacira will manufacture EXPAREL. Molteni Farmaceutici will lead regulatory, market access, and commercialization activities across the licensed territories, leveraging its established leadership and proven track record in pain management. Molteni Farmaceutici plans to launch EXPAREL sequentially, beginning with Italy, Germany, Austria, and Poland, and pursue approval in Switzerland. The first commercial sale is expected in 2027.

This partnership reflects the companies’ shared commitment to improving postsurgical pain management by combining Pacira’s differentiated product with Molteni Farmaceutici’s strong commercial execution capabilities and deep understanding of local European markets.

Locust Walk acted as the exclusive financial advisor to Pacira in the transaction.

About Molteni Farmaceutici

Molteni Farmaceutici is an Italian pharmaceutical company with a long-standing heritage of over 130 years and a strong focus on specialty care. The company is recognized for its commitment to excellence in pain management, oncology supportive care and hospital-based treatments, delivering high-quality therapies that improve patient outcomes and quality of life.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has two commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic for post-surgical pain management and ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies. Its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.

About EXPAREL^® (bupivacaine liposome injectable suspension)

EXPAREL is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older, and postsurgical regional analgesia via an interscalene brachial plexus block in adults, a sciatic nerve block in the popliteal fossa in adults, and an adductor canal block in adults. The safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks besides an interscalene brachial plexus nerve block, a sciatic nerve block in the popliteal fossa, or an adductor canal block. The product combines bupivacaine with multivesicular liposomes, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the multivesicular liposome platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.

Important Safety Information about EXPAREL for Patients

EXPAREL should not be used in obstetrical paracervical block anesthesia. In studies in adults where EXPAREL was injected into a wound, the most common side effects were nausea, constipation, and vomiting. In studies in adults where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation. In the study where EXPAREL was given to children, the most common side effects were nausea, vomiting, constipation, low blood pressure, low number of red blood cells, muscle twitching, blurred vision, itching, and rapid heartbeat. EXPAREL can cause a temporary loss of feeling and/or loss of muscle movement. How much and how long the loss of feeling and/or muscle movement depends on where and how much of EXPAREL was injected and may last for up to 5 days. EXPAREL is not recommended to be used in patients younger than 6 years old for injection into the wound, for patients younger than 18 years old, for injection near a nerve, and/or in pregnant women. Tell your health care provider if you or your child has liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from the body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL can affect the nervous system and the cardiovascular system; may cause an allergic reaction; may cause damage if injected into the joints; and can cause a rare blood disorder.

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Today, Pacira announced the granting of inducement awards on October 2, 2026 to two new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

The two employees received stock options to purchase an aggregate of 3,600 shares of Pacira common stock and restricted stock units for an aggregate of 4,200 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $25.21 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on October 1, 2027.

Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

Forward-Looking Statements 

Any statements in this press release about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “should,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the ability to realize the anticipated benefits of the divestiture of iovera®°; ‘5×30’, our growth and business strategy, our future outlook, the strength and efficacy of our intellectual property protection and patent terms, our future growth potential and future financial and operating results and trends, our plans, objectives, expectations (financial or otherwise) and intentions, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio and product development programs, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation (“NOPAIN”) Act, and any other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from these indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: risks associated with acquisitions, such as the risk that the acquired businesses and/or assets will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; risks associated with divestitures; our manufacturing and supply chain, global and United States economic conditions (including tariffs, inflation and rising interest rates), and our business, including our revenues, financial condition, cash flows and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL and ZILRETTA; the rate and degree of market acceptance of EXPAREL and ZILRETTA; the size and growth of the potential markets for EXPAREL and ZILRETTA and our ability to serve those markets; our plans to expand the use of EXPAREL and ZILRETTA to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and any of our other product candidates, including, but not limited to, PCRX-201 and PCRX-2002; the commercial success of EXPAREL and ZILRETTA; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary high-capacity adenovirus (“HCAd”) vector platform; the approval of the commercialization of our products in other jurisdictions (by either us or our partners); clinical trials in support of an existing or potential HCAd-based product candidate; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission (the “SEC”). In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the SEC.

Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com

Media Contact: Kim Hamilton, (908) 721-7067 kim.hamilton@pacira.com

Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care

By directly blocking growth hormone signaling at the receptor level, MAR002 has the potential to deliver meaningful biochemical control for a broad population of acromegaly patients

SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) — Marea Therapeutics, LLC (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the first patient has been dosed in its Phase 2 clinical trial of MAR002 for the treatment of acromegaly.

Acromegaly is a rare, chronic, progressive endocrine disorder caused by prolonged exposure to excess growth hormone (GH), most commonly due to a GH-secreting pituitary adenoma, resulting in elevated insulin-like growth factor-1 (IGF-1). It leads to the abnormal enlargement of the hands, feet, and facial features, and if left untreated, can result in severe organ damage, systemic complications, and early mortality.

MAR002 is a first-in-class allosteric monoclonal antibody investigational therapy targeting the growth hormone receptor (GHR). Data from a first-in-human Phase 1 study with MAR002 presented at the 2026 Annual Meeting of the Endocrine Society (ENDO) in June 2026 demonstrated compelling proof-of-mechanism with deep and durable IGF-1 suppression and pharmacokinetic (PK) properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care.

“Treating our first acromegaly patient with MAR002 represents an important milestone for Marea Therapeutics,” said Josh Lehrer, M.D., president and chief operating officer of Lisata Therapeutics and chief executive officer of Marea Therapeutics. “We believe MAR002 has a potential best-in-class profile and, if approved, could be transformative for the majority of acromegaly patients who cannot achieve disease control with current therapies. We are focused on clinical execution to rapidly advance this product candidate to acromegaly patients who need new treatment options.”

“People living with acromegaly often face years of symptoms before receiving a diagnosis, and even after diagnosis, many continue to struggle with the long-term burden of managing this chronic disease,” said Jill Sisco, president of Acromegaly Community, Inc. “The advancement of new treatment options that have the potential to provide effective disease control while reducing treatment burden offers hope for the acromegaly community. We are encouraged to see continued investment in investigational therapies like MAR002 that aim to address the needs and priorities of people living with this condition and expand treatment options.”

This study intends to enroll approximately 72 participants with acromegaly across three MAR002 dose arms, after an initial 900 mg loading dose, compared to placebo, with a primary endpoint of IGF-1 reduction following 10 weeks of treatment. After completing the 10-week treatment period, eligible participants will have an option to enroll in an open-label extension clinical trial.

About Acromegaly
Acromegaly is an orphan disease characterized by the excess secretion of growth hormone (GH) from a benign pituitary adenoma. Acromegaly affects approximately 30,000 patients in the U.S. If left untreated, acromegaly is highly morbid, leading to significant comorbidities such as GH-induced insulin resistance and diabetes, and serious cardiovascular pathology. The median lifespan of patients can be shortened by 10 years without effective therapy, and incomplete IGF-1 normalization is associated with increased mortality. Despite its severity, acromegaly is often under or misdiagnosed, with an average time from symptom onset to diagnosis of approximately eight years.

About MAR002
MAR002 is a potent and selective half-life-extended, allosteric, human monoclonal growth hormone receptor antagonist (GHRA) antibody being developed for the treatment of acromegaly. The in vivo PK and PD properties of MAR002 have been observed to be predictable and typical of a half-life extended human antibody, showing a long duration of action compatible with infrequent subcutaneous dose administration in humans. These characteristics support its potential to offer an effective and convenient treatment for patients with acromegaly, if approved.

About Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company’s lead product candidate, MAR001, is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The company is also advancing MAR002 in Phase 2 clinical development for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X.

About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company. Following its acquisition of Marea, Lisata’s lead product candidate is MAR001, which is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The company is also advancing MAR002 for the treatment of acromegaly.

Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Lisata and Marea. These forward-looking statements include, but are not limited to, express or implied statements relating to the company’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding expectations regarding or plans for the company’s pipeline, including its ongoing clinical trials, research and development programs and the expected timing for key milestones; and the potential benefits of its product candidates, including MAR002 and MAR001. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “aim,” “strategy,” “target,” “seek,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the company will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those uncertainties and factors described under the heading “Risk Factors” in the company’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2026, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by the company from time to time, as well as risk factors associated with companies, such as Marea, that operate in the biotechnology industry. Should one or more of these risks or uncertainties materialize, or should any of the company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Except to the extent required by applicable law, the company does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in the company.

Lisata:

Investors and Media:
John Menditto
jmenditto@lisata.com

Marea:

Media:
1AB
Katie Engleman
katie@1abmedia.com   

Investors:
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com

Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort

Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA wild-type cohort of VIKTORIA-1 and other regimens evaluated in patients with HR+/HER2- advanced breast cancer

Poster presentation of sub-group analyses from the Phase 1b trial of gedatolisib plus darolutamide in patients with mCRPC

MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that a late breaking rapid oral presentation and three poster presentations will be featured at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2026 being held October 23-27, 2026, in Madrid, Spain. Data from its clinical trials of gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”) locally advanced or metastatic breast cancer (“ABC”) and metastatic castration-resistant prostate cancer (“mCRPC”) will be presented.

Late Breaking Rapid Oral Presentation Details:

Title: VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients with HR+/HER2- advanced breast cancer (ABC) (Study 2)
Presentation Number: LBA 16
Speaker: Barbara Pistilli, MD
Session Title: Rapid oral 1: Breast cancer, advanced stage
Room: Almeria Auditorium – Hall 9
Date: Saturday, October 24, 2026
Time: 10:15 –11:45 a.m. CEST

Poster Presentation Details:

Title: A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presentation Number: 2237P
Presenting Author: Adam Sharp, MD, PhD
Session Title: Poster Display session, Metastatic prostate cancer
Date: Friday, October 23, 2026
Time: 3:15 p.m. – 4:00 p.m. CEST

Title: Gedatolisib (Ged) vs Other Regimens Post-CDK4/6i and Endocrine Therapy (ET) in PIK3CA Wild-Type (WT) HR+/ HER2- Advanced Breast Cancer (aBC): A Network Meta-Analysis (NMA)
Presentation Number: 1873P
Presenting Author: Sara Tolaney, MD
Session Title: Poster Display session, HR+ breast cancer
Date: Saturday, October 24, 2026
Time: 12:00 p.m. – 12:45 p.m. CEST

Title: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib with Endocrine Therapy (ET) and Palbociclib vs ET and Ribociclib as First-Line (1L) Treatment in Patients With HR-Positive (HR+) HER2-Negative (HER2-) Advanced Breast Cancer (ABC) (VIKTORIA-2)
Presentation Number: 57TiP
Presenting Author: Giuseppe Curigliano, MD, PhD
Session Title: Poster Display session, Advanced breast cancer, other
Date: Saturday, October 24, 2026
Time: 12:00 p.m. – 12:45 p.m. CEST

Abstracts will be published online via the ESMO website at 12:05 a.m. CEST on October 19, 2026. The posters will be presented in the Poster Area – Hall 5. Electronic versions will also be available on the ESMO 2026 virtual platform.

About Celcuity
Celcuity is a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company’s first FDA-approved product is REVTORPYK™ (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- ABC, supported FDA approval of REVTORPYK for use in patients without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of VIKTORIA-1 have been released. VIKTORIA-2 is an ongoing Phase 3 clinical trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib plus palbociclib plus fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib plus palbociclib plus letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.

Contacts: 

For Investors: 
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com   
(763) 392-0123

For investors and media:
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924

New collaboration combines Zscaler Autonomous Application Shield with Lightwell from IBM and Red Hat to help organizations reduce exposure between vulnerability disclosure and patch deployment through inline protection and validated remediation

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Zscaler, Inc. (NASDAQ: ZS), the cybersecurity platform for the AI era, today announced a collaboration with IBM and Red Hat to help organizations protect private applications during the period between vulnerability disclosure and patch deployment. The collaboration combines Zscaler Autonomous Application Shield, delivered through the Zscaler Zero Trust Exchange^TM security platform, with Lightwell from IBM and Red Hat to deliver adaptive, application-specific protection with validated software remediation in a single coordinated response.

The economics of exploitation have shifted. Capabilities that once required elite skills and weeks of manual effort are now widely available, and attackers are weaponizing newly disclosed vulnerabilities faster than enterprise patch cycles can respond. According to Mandiant’s M-Trends 2026 report, the mean time to exploit a vulnerability has fallen below zero, meaning vulnerabilities are increasingly exploited before a public patch exists. Patching remains necessary, but on its own it can no longer keep pace. Organizations need protection that can be applied at machine speed while remediation is prepared and deployed.

This collaboration extends Zscaler’s protection-first operating model for private applications, which assumes a remediation window will always exist and builds resilience around it: hide applications with Zscaler Private Access^TM (ZPA^TM) so they are harder to discover and target, segment access with Autonomous User-to-App Segmentation so a foothold does not become broad reachability, and shield reachable applications with Autonomous Application Shield so exploit attempts are stopped inline while the root cause is fixed. By uniting Zscaler Autonomous App Shield with Lightwell, the collaboration provides customers a coordinated path from immediate protection to durable fix.

Operating through the Zero Trust Exchange, Zscaler App Connectors continuously perform safe assessments of each private application’s exposure points and vulnerabilities. The Zscaler cloud individually evaluates each application, ensuring only necessary protections are applied. When a new vulnerability emerges, adaptive protections can be applied inline and in real time, without waiting for a patch. Through this collaboration, Lightwell helps Zscaler defend its customers from potential cyber threats, with Zscaler blocking exploit attempts immediately at the network level. Lightwell then provides validated remediations for affected open source software, enabling customers to fix the underlying flaw at the source.

“As attackers weaponize newly disclosed vulnerabilities faster than enterprises can respond, organizations need a way to protect private applications immediately while fixes are being prepared and deployed,” said Joby Menon, Senior Vice President of Product Management at Zscaler. “Our collaboration with IBM and Red Hat brings together inline, application-specific protection and validated remediation to help customers reduce risk during that gap.”

Through this collaboration, Zscaler, IBM, and Red Hat will deliver integrated capabilities across the application security lifecycle, addressing critical needs including:

• Exposure Discovery: Providing a current understanding of a private application’s actual risk profile, updated as fast as applications change, rather than relying on periodic scans.
• Preemptive, Application-Specific Protection: Bridging the gap between vulnerability and patching. Applying only the protections a given application needs during the gap between disclosure and patching, reducing exposure while remediation is underway and avoiding one-size-fits-all policy noise.
• Machine-Speed Response: Deploying protections inline and in real time when a new vulnerability emerges, informed by global threat intelligence from across Zscaler’s worldwide customer base.
• Validated Source-Level Remediation: Delivering tested software fixes through Lightwell so organizations can resolve the underlying vulnerability, with advisory and deployment support to prioritize and validate protections across complex environments.

“AI is shrinking the window between vulnerability discovery and vulnerability exploitation. A window that was months or weeks is now hours and minutes,” said Gunnar Hellekson, vice president and general manager, Lightwell, Red Hat. “Lightwell helps keep open source safe by patching and fixing these vulnerabilities at machine speed. Collaborating with partners like Zscaler brings Lightwell’s capabilities to the forefront of enterprise networks, mitigating potential vulnerabilities head-on while patches are applied to critical systems.”

Autonomous Application Shield is currently available through an Early Access Program. Availability, capabilities, and timing of the collaboration described herein are subject to change.

For a deeper dive into how Zscaler is helping protect against AI threats, please visit this blog.

Forward-Looking Statements

This press release contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. These forward-looking statements include the expected performance and benefits of Zscaler Autonomous Application Shield and its collaboration with IBM and Red Hat, including the delivery of adaptive, machine-speed protection for private applications. These forward-looking statements are subject to the safe harbor provisions created by the Private Securities Litigation Reform Act of 1995. A significant number of factors could cause actual results to differ materially from statements made in this press release, including those factors related to Zscaler’s ability to achieve partner and customer adoption of Autonomous Application Shield and the collaboration described herein. Additional risks and uncertainties are set forth in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on September 3, 2026, which is available on our website at ir.zscaler.com and on the SEC’s website at www.sec.gov. Any forward-looking statements in this release are based on the limited information currently available to Zscaler as of the date hereof, which is subject to change, and Zscaler will not necessarily update the information, even if new information becomes available in the future.

About Zscaler

Zscaler (NASDAQ: ZS) accelerates digital transformation so customers can be more agile, efficient, resilient, and secure. The Zscaler Zero Trust Exchange^TM platform protects thousands of customers from cyberattacks and data loss by securely connecting users, devices, and applications in any location. Distributed across 200+ public data centers globally and thousands of private sites at the edge, the SASE-based Zero Trust Exchange is the world’s largest in-line cloud security platform.

Media Contacts

Nick Gonzalez, Director of Public Relations, press@zscaler.com

Mastercard to lead customer sales engagement under worldwide agreement, expanding Rezolve Ai’s distribution and subscription revenue opportunity

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), a global leader in AI-powered commerce and engagement, today announced a worldwide reseller agreement with Mastercard, establishing a new distribution channel for Rezolve Ai’s technology as businesses prepare for the next generation of AI-driven commerce.

Under the agreement, Mastercard is authorized to market, offer and sell subscriptions to Rezolve Ai’s software and SaaS services worldwide on a non-exclusive basis. The arrangement provides a commercial framework for bringing Rezolve Ai’s capabilities to Mastercard customers with Mastercard leading coordination of the sales process and contracting directly with resale customers.

The agreement covers capabilities spanning conversational commerce, intelligent search and product discovery, catalogue enrichment, personalization, recommendations and cart and checkout orchestration. Together, these technologies help businesses connect customer intent with relevant products and support shopping journeys from discovery through checkout handoff.

Daniel M. Wagner, Founder, Chairman and CEO of Rezolve Ai, said:
“This agreement gives Rezolve Ai a powerful new engine for international growth. Mastercard can market and sell our technology worldwide, with a defined commercial framework for turning customer opportunities into deployments and subscription revenues.

“As AI agents change how people shop, merchants need technology that understands their products, represents them accurately and helps turn demand into purchases. Rezolve Ai provides that intelligence.

“We are building Rezolve Ai to become essential infrastructure for agentic commerce. This agreement is a major step in taking our technology to market at scale.”

A worldwide distribution framework
The reseller agreement provides for coordinated sales activity, including joint customer evaluations, presentations, proposals and product demonstrations, supported by Rezolve Ai’s technical expertise.

For Rezolve Ai, the arrangement creates an opportunity to extend its commercial reach through Mastercard-led customer relationships. Individual deployments, including the selected capabilities, geography and commercial terms, will be agreed through separate statements of work.

Technology for the next generation of commerce
As shopping becomes increasingly conversational and agent-driven, businesses need systems that can interpret customer requests, organize and enrich product information, personalize recommendations and coordinate the steps towards purchase.

Rezolve Ai’s technology addresses these requirements across the merchant experience. The agreement also encompasses policy controls, governance and analytics capabilities designed to support deployment within customer-defined operating requirements.

“The opportunity is to make AI-powered commerce work for businesses at scale,” Wagner added. “We believe combining our commerce intelligence with this new worldwide distribution channel can help accelerate adoption and establish Rezolve Ai at the center of that transformation.”

About Rezolve Ai

Rezolve Ai is a global leader in AI-powered commerce and engagement. Its technology helps retailers, brands, financial institutions and commerce platforms create intelligent, personalized customer experiences across search, discovery, engagement and transaction journeys.

Rezolve Ai’s platform is designed to connect consumers, merchants, banks and payment providers through intelligent commerce infrastructure that makes customer interactions more relevant, measurable and valuable. Through its AI-powered commerce capabilities and Reward’s financial engagement platform, Rezolve Ai is building the infrastructure for the next generation of personalized and agentic commerce.

Media Contact
Urmee Khan
Global Head of Communications
urmeekhan@rezolve.com
+44 7576 094 040

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the expected benefits of Rezolve Ai’s worldwide reseller agreement with Mastercard, potential customer opportunities, international expansion, adoption of the Company’s technology, growth in software and SaaS subscription revenues, and the development of agentic commerce.

These statements reflect management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These include the parties’ ability to convert sales opportunities into signed statements of work and deployments; the timing and extent of customer adoption; demand for the Company’s solutions; competition; technological and regulatory developments; and other risks described in the Company’s filings with the Securities and Exchange Commission. The reseller agreement does not guarantee customer orders, minimum purchase volumes or revenues.

Forward-looking statements speak only as of the date of this release. Rezolve Ai undertakes no obligation to update them, except as required by law.

Martela Corporation, inside information, October 5, 2026 at 15.00 (EEST)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, NEW ZEALAND, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Martela Corporation (“Martela” or the “Company“) announced on 29 September 2026 that the Company’s Extraordinary General Meeting had approved the Board of Directors’ proposals to authorise the Board of Directors to resolve on a directed share issue against consideration and the combination of share series. The Company announced on 30 September 2026 that Martela’s Board of Directors has resolved on a directed share issue against consideration of approximately EUR 6–8 million, under which it will offer for subscription, in deviation from the shareholders’ pre-emptive subscription right, initially a maximum of 17,777,777 new shares of the Company corresponding to the existing series A shares, representing the Company’s sole series of shares following the combination of share series (the “Offer Shares“) (the “Share Issue“). The subscription period for the Share Issue ended today on 5 October 2026 at 10:00 (EEST) and according to the preliminary result, Martela will receive gross proceeds of approximately EUR 7.2 million from the Share Issue.

According to the preliminary result, a total of 15,907,707 Offer Shares were subscribed for in the Share Issue, corresponding to approximately 89 per cent of the Offer Shares. The subscription price in the Share Issue was EUR 0.45 per Offer Share.

Panu Ala-Nikkola, CEO, Martela Corporation: “I would like to thank all our new and existing shareholders for their support and confidence in Martela’s future. With the proceeds from the share issue, the Company will strengthen its financial position and liquidity, while creating greater flexibility to continue the necessary development and efficiency measures. The key objective of the planned measures is to improve competitiveness, profitability and cash flow”.

The final results of the Share Issue will be published on or about 6 October 2026 after the Board of Directors of Martela has approved the subscriptions made in the Share Issue. Allocation of Offer Shares will be made in accordance with the terms and conditions of the Share Issue. As a result of the Share Issue, the combination of share series and the related directed share issue without consideration, the total number of shares in Martela will increase by a maximum of 16,058,907 from 4,639,212 to a maximum of 20,698,119 provided that the Board of Directors of Martela approves the subscriptions made in the Share Issue, the combination of the Company’s share series is registered with the Trade Register and the directed share issue without consideration is carried out at its maximum amount, i.e. 151,200 shares. The Offer Shares issued in the Share Issue amount to approximately 77 per cent of all shares in Martela following the Share Issue provided that the combination of share series is registered with the Trade Register.

The Offer Shares will be registered with the Finnish Trade Register maintained by the Finnish Patent and Registration Office on or about 12 October 2026. Trading in the Offer Shares on Nasdaq Helsinki Ltd is estimated to commence on 13 October 2026. The Offer Shares carry the right to dividends and other shareholder rights once the Offer Shares have been registered with the Trade Register. Following the registration of the combination of the share series with the Trade Register on or about 12 October 2026, the Offer Shares carry the same rights as the Company’s other shares.

Advisors

Aktia Alexander Corporate Finance Oy is acting as Martela’s financial advisor and as the Lead Manager of the Share Issue. Castrén & Snellman Attorneys Ltd is acting as Martela’s legal advisor.

MARTELA CORPORATION
BOARD OF DIRECTORS

FOR FURTHER INFORMATION, PLEASE CONTACT:

CEO, Panu Ala-Nikkola
tel +358 50 502 4728

CFO, Henri Berg
tel +358 40 836 5464

Chairman of the Board, Tapio Pajuharju
tel +358 50 5774 200
DISTRIBUTION:

NASDAQ Helsinki, key news media, www.martela.com

MARTELA CORPORATION:

Martela is a Nordic leader specialising in user-centric working and learning environments. With over 80 years of experience, we create the best places to work and offer our customers the Martela Lifecycle solutions which combine furniture and related services into a seamless whole.

IMPORTANT NOTICE:

The distribution of this release may be restricted by law and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such relevant legal restrictions. The information contained herein is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, New Zealand, Japan, Singapore, South Africa or any other jurisdiction in which the release, publication or distribution would be unlawful. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. This release is not directed to, and is not intended for release, publication or distribution to or use by, any person or entity that is a citizen or resident of, or is located in, any locality, state, country or other jurisdiction where such release, distribution, publication, availability or use would violate law or regulation or which would require any registration or licensing within such jurisdiction.

This release does not constitute a prospectus as defined in the Prospectus Regulation nor a document containing the information set out in Annex IX of the Prospectus Regulation and, as such, it does not constitute or form part of, and should not be construed as, an offer to sell, or a solicitation or invitation of any offer to buy, acquire or subscribe for, any securities or an inducement to enter into investment activity in relation to any securities.

No part of this release, nor the fact of its release, publication or distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. No representation, warranty or undertaking, expressed or implied, is made as to, and no reliance should be placed on, the pertinence, accuracy, completeness or correctness of the information or the opinions contained herein. Neither the Company nor any of its respective affiliates, advisors or representatives or any other person shall have any liability whatsoever (in negligence or otherwise) for any loss, however arising, from any use of this release or its contents or otherwise arising in connection with this release. Each person must rely on their own examination and analysis of the Company, its subsidiaries, its securities and the transactions, including the merits and risks involved.

Aktia Alexander Corporate Finance Oy acts exclusively for the Company and no one else in connection with the arrangement. Aktia Alexander Corporate Finance Oy does not regard any other person as its client in relation to the arrangement. Aktia Alexander Corporate Finance Oy is not responsible to anyone other than the Company for providing the protections afforded to its clients, nor for giving advice in relation to the arrangement or any transaction or arrangement referred to herein.

This release includes forward-looking statements. These statements may not be based on historical facts, but are statements about future expectations. When used in this release, the words “aims,” “anticipates,” “assumes,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “should,” “will,” “would” and similar expressions as they relate to the Company and the transactions identify certain of these forward-looking statements. Other forward-looking statements can be identified in the context in which the statements are made. These forward-looking statements are based on present plans, estimates, projections and expectations and are not guarantees of future performance. They are based on certain expectations, which, even though they seem to be reasonable at present, may turn out to be incorrect. Such forward-looking statements are based on assumptions and are subject to various risks and uncertainties. Readers should not rely on these forward-looking statements. Numerous factors may cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied in the forward-looking statements. Neither the Company nor any of its affiliates, advisors, representatives or any other person undertakes any obligation to review, confirm or to publicly release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise following the date of this release.